search
Back to results

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Primary Purpose

Psoriasis

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BMS-986322
Placebo
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psoriasis focused on measuring Moderate-to-Severe Psoriasis, BMS-986322, TYK2 inhibitor

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of plaque psoriasis (PsO) for ≥ 6 months Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs) Deemed by Investigator to be eligible for phototherapy or systemic therapy Psoriatic plaques must cover ≥ 10% of body surface area at baseline Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline Exclusion Criteria: Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply

Sites / Locations

  • Total Skin and Beauty Dermatology Center, PCRecruiting
  • Alliance Dermatology
  • Raoof MDRecruiting
  • First OC Dermatology - Fountain ValleyRecruiting
  • Center For Dermatology Clinical Research, Inc.Recruiting
  • Dermatology Research Associates - Howard Sofen, MDRecruiting
  • Wallace Skin & Body InstituteRecruiting
  • Southern California Dermatology, IncRecruiting
  • Florida Academic Dermatology CenterRecruiting
  • Coral Gables Dermatology & Aesthetics
  • Renstar Medical Research
  • NorthShore Medical Group - Dermatology - Skokie
  • Dermatology Specialists Research - IndianaRecruiting
  • Allcutis Research, LLC - BeverlyRecruiting
  • Allcutis Research, LLC - 155 BorthwickRecruiting
  • Duke Dermatology South DurhamRecruiting
  • Case Western Reserve UniversityRecruiting
  • Palmetto Clinical Trial Services, LLC - Greenville
  • Center for Clinical Studies (CCS) - Webster/Clear Lake LocationRecruiting
  • Premier Clinical Research
  • Local Institution - 0024Recruiting
  • Local Institution - 0019Recruiting
  • Local Institution - 0045Recruiting
  • Local Institution - 0034Recruiting
  • Local Institution - 0020Recruiting
  • Local Institution - 0041Recruiting
  • Local Institution - 0015
  • Local Institution - 0030Recruiting
  • Local Institution - 0022
  • Local Institution - 0028
  • Local Institution - 0018
  • Local Institution - 0021
  • Local Institution - 0052
  • Local Institution - 0038
  • Local Institution - 0036
  • Local Institution - 0053
  • Local Institution - 0048
  • Local Institution - 0049Recruiting
  • Local Institution - 0042Recruiting
  • Local Institution - 0051
  • Local Institution - 0023
  • Local Institution - 0026Recruiting
  • Local Institution - 0027Recruiting
  • Local Institution - 0035
  • Local Institution - 0031
  • Local Institution - 0039
  • Local Institution - 0033
  • Local Institution - 0043
  • Local Institution - 0040
  • Local Institution - 0017
  • Local Institution - 0025
  • Local Institution - 0037
  • Local Institution - 0046
  • Local Institution - 0054
  • Local Institution - 0047
  • Local Institution - 0050

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

BMS-986322 Dose 1

BMS-986322 Dose 2

BMS-986322 Dose 3

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Proportion of participants achieving 75% reduction in PASI score (PASI-75)
Number of participants with treatment-emergent adverse event (TEAEs)
Number of participants with serious adverse events (SAEs)
Number of participants with TEAEs leading to treatment discontinuation
Number of participants with clinical laboratory abnormalities
Number of participants with electrocardiogram (ECG) abnormalities
Number of participants with vital sign abnormalities
Number of participants with physical examination abnormalities

Secondary Outcome Measures

Proportion of participants achieving sPGA score of 0 or 1
Proportion of participants achieving 50% reduction in PASI score (PASI-50)
Proportion of participants achieving 90% reduction in PASI score (PASI-90)
Proportion of participants achieving 100% reduction in PASI score (PASI-100)
Proportion of participants achieving PASI-50
Proportion of participants achieving PASI-75
Proportion of participants achieving PASI-90
Proportion of participants achieving PASI-100
Change from baseline in PASI score
BMS-986322 trough concentrations
Maximum observed plasma concentration (Cmax) of BMS-986322
Area under the plasma concentration-time curve over the dosing interval [AUC(TAU)] of BMS-986322
Time of maximum observed plasma concentration (Tmax) of BMS-986322

Full Information

First Posted
February 7, 2023
Last Updated
September 28, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT05730725
Brief Title
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Official Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 3, 2023 (Actual)
Primary Completion Date
May 30, 2024 (Anticipated)
Study Completion Date
May 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psoriasis
Keywords
Moderate-to-Severe Psoriasis, BMS-986322, TYK2 inhibitor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BMS-986322 Dose 1
Arm Type
Experimental
Arm Title
BMS-986322 Dose 2
Arm Type
Experimental
Arm Title
BMS-986322 Dose 3
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
BMS-986322
Intervention Description
Specified dose on specified days
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Specified dose on specified days
Primary Outcome Measure Information:
Title
Proportion of participants achieving 75% reduction in PASI score (PASI-75)
Time Frame
At week 12
Title
Number of participants with treatment-emergent adverse event (TEAEs)
Time Frame
Up to 16 weeks
Title
Number of participants with serious adverse events (SAEs)
Time Frame
Up to 16 weeks
Title
Number of participants with TEAEs leading to treatment discontinuation
Time Frame
Up to 16 weeks
Title
Number of participants with clinical laboratory abnormalities
Time Frame
Up to 16 weeks
Title
Number of participants with electrocardiogram (ECG) abnormalities
Time Frame
Up to 16 weeks
Title
Number of participants with vital sign abnormalities
Time Frame
Up to 16 weeks
Title
Number of participants with physical examination abnormalities
Time Frame
Up to 16 weeks
Secondary Outcome Measure Information:
Title
Proportion of participants achieving sPGA score of 0 or 1
Time Frame
At week 12
Title
Proportion of participants achieving 50% reduction in PASI score (PASI-50)
Time Frame
At week 12
Title
Proportion of participants achieving 90% reduction in PASI score (PASI-90)
Time Frame
At week 12
Title
Proportion of participants achieving 100% reduction in PASI score (PASI-100)
Time Frame
At week 12
Title
Proportion of participants achieving PASI-50
Time Frame
Up to week 12
Title
Proportion of participants achieving PASI-75
Time Frame
Up to week 12
Title
Proportion of participants achieving PASI-90
Time Frame
Up to week 12
Title
Proportion of participants achieving PASI-100
Time Frame
Up to week 12
Title
Change from baseline in PASI score
Time Frame
Up to week 12
Title
BMS-986322 trough concentrations
Time Frame
Up to week 12
Title
Maximum observed plasma concentration (Cmax) of BMS-986322
Time Frame
At day 15
Title
Area under the plasma concentration-time curve over the dosing interval [AUC(TAU)] of BMS-986322
Time Frame
At day 15
Title
Time of maximum observed plasma concentration (Tmax) of BMS-986322
Time Frame
At day 15

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of plaque psoriasis (PsO) for ≥ 6 months Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs) Deemed by Investigator to be eligible for phototherapy or systemic therapy Psoriatic plaques must cover ≥ 10% of body surface area at baseline Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline Exclusion Criteria: Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone
855-907-3286
Email
Clinical.Trials@bms.com
First Name & Middle Initial & Last Name or Official Title & Degree
First line of the email MUST contain NCT # and Site #.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Total Skin and Beauty Dermatology Center, PC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205-5021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Krell, Site 0006
Phone
205-380-6149
Facility Name
Alliance Dermatology
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032-2239
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Raoof MD
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
TOORAJ RAOOF, Site 0012
Phone
818-788-5060
Facility Name
First OC Dermatology - Fountain Valley
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708-3701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivian Laquer, Site 0005
Phone
714-531-2966
Facility Name
Center For Dermatology Clinical Research, Inc.
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sunil Dhawan, Site 0002
Phone
510-599-4750
Facility Name
Dermatology Research Associates - Howard Sofen, MD
City
Los Angeles
State/Province
California
ZIP/Postal Code
90045-3606
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Howard Sofen, Site 0001
Facility Name
Wallace Skin & Body Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90056
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Wallace, Site 0016
Facility Name
Southern California Dermatology, Inc
City
Santa Ana
State/Province
California
ZIP/Postal Code
92701-2201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Soung, Site 0003
Phone
714-474-2174
Facility Name
Florida Academic Dermatology Center
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134-5736
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francisco Kerdel, Site 0013
Facility Name
Coral Gables Dermatology & Aesthetics
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Individual Site Status
Withdrawn
Facility Name
Renstar Medical Research
City
Ocala
State/Province
Florida
ZIP/Postal Code
34470-6657
Country
United States
Individual Site Status
Withdrawn
Facility Name
NorthShore Medical Group - Dermatology - Skokie
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60077-1049
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Mehlis, Site 0056
Phone
847-663-8530
Facility Name
Dermatology Specialists Research - Indiana
City
Clarksville
State/Province
Indiana
ZIP/Postal Code
47129-2201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Megan Vissing, Site 0044
Facility Name
Allcutis Research, LLC - Beverly
City
Beverly
State/Province
Massachusetts
ZIP/Postal Code
01915-1672
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Greenstein, Site 0004
Phone
19789789696897
Facility Name
Allcutis Research, LLC - 155 Borthwick
City
Portsmouth
State/Province
New Hampshire
ZIP/Postal Code
03801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abel Jarell, Site 0007
Phone
603-319-8863
Facility Name
Duke Dermatology South Durham
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27713-8507
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Murray, Site 0055
Phone
919-684-2393
Facility Name
Case Western Reserve University
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neil Korman, Site 0008
Facility Name
Palmetto Clinical Trial Services, LLC - Greenville
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615-3514
Country
United States
Individual Site Status
Withdrawn
Facility Name
Center for Clinical Studies (CCS) - Webster/Clear Lake Location
City
Webster
State/Province
Texas
ZIP/Postal Code
77598-4927
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Tyring, Site 0011
Phone
713-528-8818
Facility Name
Premier Clinical Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202-1461
Country
United States
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0024
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0024
Facility Name
Local Institution - 0019
City
Carlton
State/Province
Victoria
ZIP/Postal Code
3053
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0019
Facility Name
Local Institution - 0045
City
Pascoe Vale South
State/Province
Victoria
ZIP/Postal Code
3044
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0045
Facility Name
Local Institution - 0034
City
Barrie
State/Province
Ontario
ZIP/Postal Code
L4M 7G1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0034
Facility Name
Local Institution - 0020
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 3C3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0020
Facility Name
Local Institution - 0041
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 2C2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0041
Facility Name
Local Institution - 0015
City
Richmond Hill
State/Province
Ontario
ZIP/Postal Code
L4C 9M7
Country
Canada
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0030
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M2N 3A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0030
Facility Name
Local Institution - 0022
City
Novy Jicin
State/Province
CZ
ZIP/Postal Code
741 01
Country
Czechia
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0028
City
Ostrava
State/Province
MO
ZIP/Postal Code
70200
Country
Czechia
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0018
City
Prague
ZIP/Postal Code
100 00
Country
Czechia
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0021
City
Prague
ZIP/Postal Code
110 00
Country
Czechia
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0052
City
Reims
State/Province
Marne
ZIP/Postal Code
51100
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0038
City
Martigues
ZIP/Postal Code
13500
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0036
City
Rouen
ZIP/Postal Code
76031
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0053
City
Saint-Priest-En-Jarez
ZIP/Postal Code
42270
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0048
City
Toulon
ZIP/Postal Code
83000
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0049
City
Sapporo-Shi
State/Province
Hokkaido
ZIP/Postal Code
064-0807
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0049
Facility Name
Local Institution - 0042
City
Itabashi-Ku
State/Province
Tokyo
ZIP/Postal Code
173-8610
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0042
Facility Name
Local Institution - 0051
City
Fukuoka-shi
ZIP/Postal Code
814-0180
Country
Japan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0051
Facility Name
Local Institution - 0023
City
Itabashi-Ku
ZIP/Postal Code
173-8606
Country
Japan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0023
Facility Name
Local Institution - 0026
City
Nagoya-Shi
ZIP/Postal Code
467-8602
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0026
Facility Name
Local Institution - 0027
City
Tsu City
ZIP/Postal Code
514-8507
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0027
Facility Name
Local Institution - 0035
City
Wroclaw
State/Province
DS
ZIP/Postal Code
50-566
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0031
City
Wroclaw
State/Province
DS
ZIP/Postal Code
51-685
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0039
City
Lodz
State/Province
LD
ZIP/Postal Code
90-265
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0033
City
Lodz
State/Province
LD
ZIP/Postal Code
90-419
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0043
City
Warszawa
State/Province
MZ
ZIP/Postal Code
01-142
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0040
City
Warszawa
State/Province
MZ
ZIP/Postal Code
01-817
Country
Poland
Individual Site Status
Active, not recruiting
Facility Name
Local Institution - 0017
City
Warszawa
State/Province
MZ
ZIP/Postal Code
02-962
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0025
City
Lodz
ZIP/Postal Code
90-436
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0037
City
Barcelona
ZIP/Postal Code
08040
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0046
City
Leytonstone
State/Province
LND
ZIP/Postal Code
E11 1NR
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0046
Facility Name
Local Institution - 0054
City
London
State/Province
LND
ZIP/Postal Code
N20 9EX
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0054
Facility Name
Local Institution - 0047
City
Liverpool
State/Province
Merseyside
ZIP/Postal Code
L1 9ED
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0047
Facility Name
Local Institution - 0050
City
Hinckley
ZIP/Postal Code
LE102SE
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0050

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trialsand research/disclosurecommitment.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

We'll reach out to this number within 24 hrs